The Journal of Practical Medicine >

2024 , Vol. 40 >Issue 16: 2277 - 2283

DOI: https://doi.org/10.3969/j.issn.1006-5725.2024.16.013

Basic Research

Effect of miR⁃217 targeting FOXO3 on the resistance of non⁃small cell lung cancer to gefitinib and its related mechanisms

  • Lun ZHAO ,
  • Xin ZHAO ,
  • Chenchen LIN ,
  • Qi FU ,
  • Mohan SHI ,
  • Haoran. ZHANG
Expand
  • Internal Medicine?Oncology，the First Affiliated Hospital of Bengbu Medical College，Bengbu 233003，China

Received date: 2023-11-12

  Online published: 2024-08-26

Fold

Abstract

Objective To investigate the effect of miR?217 on gefitinib resistance in non?small cell lung cancer （NSCLC）， and to explore the downstream target genes and related pathways. Methods qRT?PCR was used to detect the expression of miR?217 in human lung normal epithelial cell lines BEAS?2B， NSCLC cell lines A549， HCC827， PC9， NCI?H1975 and gefitinib resistant strain PC9/GR. PC9/GR cells were selected and the cells of control group， NC?mimic group， miR?217 mimic group， miR?217 mimic + si?NC group， and miR?217 mimic + si?FOXO3 group were constructed using liposome transfection technique. CCK8 and clonal formation assay were used to detect changes in cell proliferation capacity， flow cytometry was used to detect changes in cell apoptosis capacity， and western blot was used to detect protein expression related to PI3K/AKT signaling pathway. The Targetscan bioinformatics website predicted the downstream target genes of miR?217， and the correlation between miR?217 and the target gene FOXO3 was detected by dual luciferase assay. Results Compared with BEAS?2B cells， the expression of miR?217 in A549， HCC827， PC9 and NCI?H1975 cells was significantly decreased （P < 0.05）. With the increase of gefitinib concentration， the expression of miR?217 gene in PC9 cells was gradually decreased （P < 0.05）， and the expression of miR?217 in PC9/GR cells was lower than that in PC9 （P < 0.05）. Compared with the control group and NC?mimic group， the cell proliferation capacity of miR?217 mimic group was significantly decreased （P < 0.05）， the number of apoptosis was increased （P < 0.05）， and the expression levels of p?PI3K and p?AKT were decreased （P < 0.05）. Dual luciferase reporter gene assay proved that FOXO3 is the target of miR?217. Compared with miR?217 mimic group and miR?217 mimic + si?NC group， the cell drug resistance of miR?217 mimic + si?FOXO3 group was increased （P < 0.05）， the proliferation ability was significantly increased （P < 0.05）， and the number of apoptosis was decreased （P < 0.05）. The expression levels of P?PI3K and P?AKT were increased （P < 0.05）. Conclusion Overexpression of miR?217 reversed the resistance of PC9/GR to gefitinib in NSCLC cells and inhibited the proliferation and accelerated apoptosis of PC9/GR cells， which may be related to the regulation of PI3K/AKT signaling pathway by targeting FOXO3.

Key words： NSCLC; miR?217; FOXO3; PI3K/AKT signaling pathway

Cite this article

Lun ZHAO , Xin ZHAO , Chenchen LIN , Qi FU , Mohan SHI , Haoran. ZHANG . Effect of miR⁃217 targeting FOXO3 on the resistance of non⁃small cell lung cancer to gefitinib and its related mechanisms[J]. The Journal of Practical Medicine, 2024 , 40(16) : 2277 -2283 . DOI: 10.3969/j.issn.1006-5725.2024.16.013

References

1 NOORELDEEN R， BACH H. Current and Future Development in Lung Cancer Diagnosis［J］. Int J Mol Sci，2021，22（16）：8661. doi:10.3390/ijms22168661
2 BADE B C， DELA CRUZ C S. Lung Cancer 2020：Epidemiology，Etiology，and Prevention［J］. Clin Chest Med，2020，41（1）：1-24. doi:10.1016/j.ccm.2019.10.001
3 邓建华，陈瑞，李道生，等. ADGRD1抑制非小细胞肺癌细胞增殖和转移的作用及其分子机制［J］. 实用医学杂志，2023，39（5）：550-556.
4 朱明雪，闫清，王鹏，等. EGFR突变对肺腺癌预后及治疗意义生物信息分析［J］. 青岛大学学报（医学版），2023，59（4）：522-526.
5 SUN C， GAO W， LIU J，et al. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer［J］. Respir Res，2020，21（1）：210. doi:10.1186/s12931-020-01477-y
6 PAN Z， WANG K， WANG X，et al. Cholesterol promotes EGFR-TKIs resistance in NSCLC by inducing EGFR/Src/Erk/SP1 signaling-mediated ERRα re-expression［J］. Mol Cancer， 2022，21（1）：77. doi:10.1186/s12943-022-01547-3
7 徐佳欢，王新年，黄新，等. 晚期非小细胞肺癌一线吉非替尼治疗后的耐药时间分析［J］. 实用药物与临床，2020，23（3）：224-229.
8 HE B， ZHAO Z， CAI Q，et al. miRNA-based biomarkers， therapies， and resistance in Cancer［J］. Int J Biol Sci，2020，16（14）：2628-2647. doi:10.7150/ijbs.47203
9 HILL M， TRAN N. miRNA interplay： mechanisms and consequences in cancer［J］. Dis Model Mech，2021，14（4）：dmm047662. doi:10.1242/dmm.047662
10 宿伟鹏，赵化荣，李晨曦，等. miR-217靶向调控HMGA2基因对内质网应激介导的口腔癌细胞自噬与凋亡的影响［J］. 西部医学，2023，35（9）：1256-1263.
11 匡婷，康佳文，郭思慧，等. 外泌体miR-217通过下调E-cadherin对宫颈癌Siha细胞淋巴管新生的影响［J］. 湖南师范大学学报（医学版），2021，18（3）：1-4. doi:10.3969/j.issn.1673-016X.2021.03.001
12 JIANG W， HOU L， WEI J，et al. Hsa-miR-217 Inhibits the Proliferation， Migration， and Invasion in Non-small Cell Lung Cancer Cells Via Targeting SIRT1 and P53/KAI1 Signaling［J］. Balkan Med J，2020，37（1）：208-214. doi:10.4274/balkanmedj.galenos.2020.2019.9.91
13 FITZWALTER B E， THORBURN A. FOXO3 links autophagy to apoptosis［J］. Autophagy， 2018，14（8）：1467-1468. doi:10.1080/15548627.2018.1475819
14 LIN Z， NIU Y， WAN A，et al. RNA m6A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy［J］. EMBO J，2020，39（12）：e103181. doi:10.15252/embj.2019103181
15 YU C， HODGE A M， WONG E M，et al. Association of FOXO3 Blood DNA Methylation with Cancer Risk，Cancer Survival，and Mortality［J］. Cells，2021，10（12）：3384. doi:10.3390/cells10123384
16 AN Y， WANG B， WANG X，et al. SIRT1 inhibits chemoresistance and cancer stemness of gastric cancer by initiating an AMPK/FOXO3 positive feedback loop［J］. Cell Death Dis，2020，11（2）：115. doi:10.1038/s41419-020-2308-4
17 SIEGEL R L， MILLER K D， JEMAL A. Cancer statistics， 2020［J］. CA Cancer J Clin，2020，70（1）：7-30. doi:10.3322/caac.21590
18 TAN A C， TAN D S W. Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations［J］. J Clin Oncol，2022，40（6）：611-625. doi:10.1200/jco.21.01626
19 焦海晶，李珍，黄少冰，等. PAK3通过激活ERK1活性介导非小细胞肺癌对吉非替尼耐药［J］. 现代肿瘤医学，2023，31（21）：3901-3907. doi:10.3969/j.issn.1672-4992.2023.21.001
20 ZHOU S， ZHU C， PANG Q，et al. MicroRNA-217：A regulator of human cancer［J］. Biomed Pharmacother，2021，133：110943. doi:10.1016/j.biopha.2020.110943
21 JIANG B， ZHU S J， XIAO S S，et al. MiR-217 Inhibits M2-Like Macrophage Polarization by Suppressing Secretion of Interleukin-6 in Ovarian Cancer［J］. Inflammation，2019，42（5）：1517-1529. doi:10.1007/s10753-019-01004-2
22 HE S， WANG Z， TANG H，et al. MiR-217 Inhibits Proliferation，Migration，and Invasion by Targeting SIRT1 in Osteosarcoma［J］.Cancer Biother Radiopharm，2019，34（4）：264-270. doi:10.1089/cbr.2017.2394
Options
Outlines

/

〈 〉